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Prognostic significance of multiple kallikreins
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Abstract
Background: Kallikreins have clinical value as prognostic markers in a subset of malignancies examined to date,
including kallikrein 3 (prostate specific antigen) in prostate cancer. We previously demonstrated that kallikrein 6 is
expressed at higher levels in grade IV compared to grade III astrocytoma and is associated with reduced survival of
GBM patients.
Methods: In this study we determined KLK1, KLK6, KLK7, KLK8, KLK9 and KLK10 protein expression in two
independent tissue microarrays containing 60 grade IV and 8 grade III astrocytoma samples. Scores for staining
intensity, percent of tumor stained and immunoreactivity scores (IR, product of intensity and percent) were
determined and analyzed for correlation with patient survival.
Results: Grade IV glioma was associated with higher levels of kallikrein-immunostaining compared to grade III
specimens. Univariable Cox proportional hazards regression analysis demonstrated that elevated KLK6- or KLK7-IR
was associated with poor patient prognosis. In addition, an increased percent of tumor immunoreactive for KLK6 or
KLK9 was associated with decreased survival in grade IV patients. Kaplan-Meier survival analysis indicated that
patients with KLK6-IR < 10, KLK6 percent tumor core stained < 3, or KLK7-IR < 9 had a significantly improved survival.
Multivariable analysis indicated that the significance of these parameters was maintained even after adjusting for
gender and performance score.
Conclusions: These data suggest that elevations in glioblastoma KLK6, KLK7 and KLK9 protein have utility as
prognostic markers of patient survival.
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Background
Expression levels of select kallikreins (KLK) are pro-
posed or already used as biomarkers in human malig-
nancies, including prostate, ovarian or breast cancers.
KLKs are a family of secreted serine proteases, consist-
ing of 15 genes located in a contiguous cluster on
chromosome 19q13.4 [1]. KLKs participate in trypsin- or
chymotrypsin-like protein cleavage, leading to extracel-
lular matrix degradation and tissue remodeling, activa-
tion or inactivation of other protease family members,
or in some cases, activation of protease activated
receptors (PARs) to elicit intracellular signaling and de-
fined cellular responses [2]. For example, elevated levels
of KLK6 are associated with higher grade, later stage and
serous histotype ovarian cancer, all of which are associ-
ated with an unfavorable prognosis [3]. KLK3 (prostate
specific antigen (PSA)) serves as a well-recognized
serum biomarker for prostate cancer [4]. Providing the
rationale for the current study, we recently demon-
strated that elevated levels of KLK6 are associated with
high-grade glioma and poor patient survival [5]. Very lit-
tle is known regarding the potential prognostic signifi-
cance of other kallikrein family members in glial tumors
and here we examined the association of 6 kallikreins
with GBM grade and patient survival.
The location of kallikrein family members on human
chromosome 19q makes them of particular interest in
glioma, given the frequency of copy number variations
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in glioma patient tumors [6, 7]. Whole arm loss of
chromosome 19q has been linked to better survival in
oligodendroglioma, although smaller deletions have not
been shown to have the same survival benefit [8, 9].
Conversely, gain of chromosome 19 in glioblastoma has
been correlated with a poor prognosis [10], an effect at-
tributed to radiation resistance [11]. In this regard it is
of interest that not only are levels of KLK6 significantly
elevated in high-grade glioma (glioblastoma multiforme
(GBM), grade IV astrocytoma) and associated with poor
patient survival, but in addition KLK6 promotes the re-
sistance of glioma cells to a wide variety of cell death-
inducing agents, including staurosporine, cisplatin,
radiation and temozolomide [5]. The potential patho-
physiological significance of KLK6 to glioma appears to
extend to lower grade tumors as well, since patients
with mixed intracranial tumors positive for KLK6 ex-
pression also have unfavorable prognoses compared to
those lacking expression [12]. Interestingly, patients
with KLK7 positive tumors also survived for shorter in-
tervals post-surgery relative to patients in which no
KLK7 expression was detected [13]. By contrast, tumor
KLK8 RNA expression in the same patient cohort was
not associated with survival [13].
Given the established prognostic significance of KLK6
to GBM patient survival, taken with the association of
other KLKs with a variety of CNS tumor types, we made
a comprehensive examination of five additional kalli-
kreins in the patient cohort previously utilized to deter-
mine the prognostic significance of KLK6. Like KLK6,
higher levels of KLK1, KLK7, KLK8, KLK9 and KLK10
were all found to be associated with higher astrocytoma
grade. In addition, high tumor levels of KLK7-IR, were,
like KLK6, found to be associated with reduced patient
survival. These findings suggest that multiple kallikreins
are positioned to play roles in the pathophysiology of
high-grade glioma and that future studies are needed to




The tissue microarrays containing grade III and grade IV
astrocytoma specimens utilized in this study were previ-
ously described in detail [5]. Briefly, surgically resected
astrocytoma samples were formalin-fixed and paraffin-
embedded prior to examination by a neuropathologist
(CG) to determine grade III or grade IV status based on
WHO criteria. Astrocytoma samples were arranged
across two tissue independent microarrays in triplicate.
One array contained 38 grade IV astrocytomas and the
second 22 grade IV and 8 grade III astrocytomas. Five-
micron paraffin sections were cut for immunohistochemi-
cal localization of kallikreins. Patient demographics are
provided in Additional file 1: Table S1, including age at
surgery, gender and Eastern Cooperative Oncology
Group (ECOG) performance score. Mayo Clinic Institu-
tional Review Board approved the use of all human ma-
terials utilized in this study. Informed written consent
was obtained prior to donation of tissue.
Immunohistochemical analysis
To determine the expression of kallikrein proteins in
grade III and IV astrocytoma, tissue microarrays were
immunostained using antibodies specific to KLK1,
KLK6, KLK7, KLK8, KLK9, or KLK10 [14–16]. Deparaf-
finized sections were treated with 0.3 % hydrogen perox-
ide in methanol, followed by rehydration in graded ethyl
alcohols. Primary antibodies for each kallikrein were
applied for 18 h at 4 C. KLK1 immunoreactivity was
detected using a mouse monoclonal antibody M01-
H00003816 (Novus Biologicals, Littleton, CO). KLK6
was detected using a KLK6-specific monoclonal antibody
(MSP-3-3) [14–16]. KLK7 [17, 18], KLK8 [19] and
KLK10 [17] were detected with previously generated and
validated rabbit polyclonal antibodies [20, 21]. KLK9 was
detected using a rabbit polyclonal antibody PAB-10236
(Orbigen, San Diego, CA). Species appropriate biotinyl-
ated secondary antibodies (Jackson ImmunoResearch
Laboratories, West Grove, PA) followed by peroxidase-
conjugated streptavidin (Dako, Carpinteria, CA) and
standard 3',3'-diaminobenzadine tetrahydrochloride im-
munohistochemistry were used to visualize kallikrein
specific immunoreactivity. All immunostained tissue sec-
tions were counterstained with Gills hematoxylin.
All stained sections were imaged with a Bliss digital
imaging system pairing an Axioplan microscope (Zeiss,
Jena, Germany) with a slide scanner (Bacus Laboratories,
Center Valley, PA). Two independent observers com-
pleted scoring without knowledge of tumor demograph-
ics. Scoring parameters consisted of the staining
intensity (range 1-3: low, medium and high) and the per-
cent tumor core stained (range 1–4: 25 % increments).
An IR score was calculated as the product of the staining
intensity and percent stained. Scores from multiple cores
from each tumor across the two observers were averaged
[5]. Additional high-resolution images were prepared
using a BX51 microscope (Olympus, Center Valley, PA)
with a 100x-oil immersion objective and DP72 camera
(Olympus).
Statistical analysis
Kallikrein staining parameters in grade III and IV as-
trocytoma were compared using the Kruskal-Wallis
test. Cumulative survival probabilities were estimated
using the Kaplan-Meier method. Cox proportional
hazards regression was used to assess the association
of kallikrein staining parameters with survival in the
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grade 4 astrocytomas. Both univariable and multivari-
able analyses were completed including age, gender
and ECOG performance score as covariates. Analysis
of Martingale residuals from the Cox proportional haz-
ards regression models were used to assess the func-
tional form of kallikrein parameters. Appropriate cut
points for kallikrein parameters were determined based
on this analysis (22). The cut points established were
utilized to create survival curves using the Kaplan-
Meier method. The dichotomized kallikrein parame-
ters were then assessed using Cox proportional hazards
regression as described above. In all analyses, P < 0.05
was considered significant.
Results
Kallikrein protein expression is increased in grade IV
astrocytoma
Expression of KLK1, KLK6, KLK7, KLK8, KLK9 and
KLK10 protein was assessed by immunohistochemical
analysis of grade III (n = 8) and grade IV (n = 60, n = 55 for
KLK1) astrocytoma samples. The mean age was 48.1
(range 34–73) and 58.1 (range 33–84) for the grade III
and grade IV patients, respectively. Grade III patients were
62.5 % female and grade IV patients were 36.7 % female.
Additional demographic data regarding age, gender, extent
of resection and ECOG performance scores are contained
in Additional file 1: Table S1. All samples received a score
for the intensity of the immunohistochemical staining,
percent of the tissue core stained, and an IR score that is
the product of the staining intensity and percent stained
[5]. The range, median and distribution of scores are pro-
vided as box and whisker plots for each kallikrein by grade
(Fig. 1). The most intense KLK-IR was seen in the grade
IV tumors with antibodies recognizing KLK1, KLK6,
KLK7 and KLK9. The intensity of immunoreactivity for
KLK8 and KLK10 were low relative to the other kallikreins
examined (see also Fig. 2).
To assess potential differences in kallikrein immunore-
activity across grade III and grade IV tumors, the mean
scores for staining intensity, percent of tumor core
stained, and IR scores were compared using the Kruskal-
Wallis test (Table 1). The mean intensity and IR scores
were significantly higher in grade IV compared to grade
III for all kallikreins examined (Table 1; P < 0.03,
Kruskal-Wallis test). Also, the mean percent tumor core
stained was significantly higher in grade IV relative to
grade III for KLK6 (Table 1; P = 0.0005, Kruskal-Wallis
test). The mean percent tumor core stained was signifi-
cantly higher in grade III compared to grade IV for
KLK8 (Table 1; P = 0.0038, Kruskal-Wallis test). The
Fig. 1 Immunohistochemical scores for KLK1, KLK6, KLK7, KLK8, KLK9 and KLK10 in grade IV versus grade III astrocytomas. Immunohistochemical
scores for intensity (I), percent (%) and immunoreactivity score (IR) are shown as box and whisker plots. *P < 0.05, **P < 0.01 and ***P < 0.001;
Kruskal-Wallis test. Mean and standard deviations are provided in Table 1
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mean percent tumor core stained for KLK1, KLK7,
KLK9 or KLK10 across grades III and IV were not sig-
nificantly different.
The appearance of immunohistochemical staining for
KLK1, KLK6, KLK7, KLK8, KLK9 and KLK10 in grade
III and grade IV astrocytoma is shown in Fig. 2. As
expected, immunoreactivity for each kallikrein was clearly
visualized cytoplasmically. In addition, variable levels of
extracellular staining were also apparent with the most in-
tense extracellular staining seen in the case of KLK9, KLK7
and KLK6. In general, extracellular staining appeared the
most intense in the higher grade gliomas (Fig. 2).
Fig. 2 Immunohistochemical staining for KLK1, KLK6, KLK7, KLK8, KLK9 and KLK10 in astrocytomas. Representative photomicrographs of grade III
astrocytomas (a–l) and grade IV astrocytomas (m–x) stained for KLK1 (a, g, m and s), KLK6 (b, h, n and t), KLK7 (c, i, o and u), KLK8 (d, j, p and v), KLK9
(e, k, q and w), or KLK10 (f, l, r and x). Images provided at low (a–f and m–r, scale bar = 50 μm) and high magnification (g–l and s–x,
scale bar = 10 μm)
Table 1 Immunohistochemical scores for KLK1, KLK6, KLK7, KLK8, KLK9 and KLK10 in astrocytoma patients
Intensity ± SD Percent ± SD IR ± SD
III IV Pa III IV Pa III IV Pa
KLK1 1.7 ± 0.4 2.2 ± 0.4 0.0063** 3.7 ± 0.4 3.3 ± 0.7 0.096 5.4 ± 1.8 7.3 ± 2.4 0.031*
KLK6 1.5 ± 0.7 2.6 ± 0.4 0.0003*** 2.0 ± 0.6 3.0 ± 0.7 0.0005*** 2.4 ± 1.5 7.7 ± 2.4 <0.0001***
KLK7 2.0 ± 0.1 2.3 ± 0.4 0.0042** 3.9 ± 0.2 3.7 ± 0.4 0.057 5.9 ± 1.1 8.2 ± 2.1 0.003**
KLK8 1.1 ± 0.2 1.5 ± 0.5 0.0099** 3.8 ± 0.5 3.0 ± 0.8 0.0038** 3.0 ± 0.7 4.3 ± 1.6 0.022*
KLK9 1.4 ± 0.6 2.4 ± 0.5 0.0003*** 3.4 ± 0.7 3.6 ± 0.5 0.42 4.6 ± 1.8 9.0 ± 1.9 0.0001***
KLK10 1.0 ± 0.0 1.4 ± 0.4 0.0012** 2.5 ± 1.2 3.0 ± 0.7 0.36 2.4 ± 1.4 3.9 ± 1.5 0.011*
Mean and standard deviation of KLK1, KLK6, KLK7, KLK8, KLK9 and KLK10 staining intensity, percent tumor core stained and immunoreactivity score across 60
grade IV astrocytoma specimens
*P < 0.05, **P < 0.01 and ***P < 0.001
aKruskal-Wallis test
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Association of kallikrein immunoreactivity with survival in
grade IV astrocytoma
To determine the potential impact of differential kalli-
krein protein expression on patient survival, univariable
Cox proportional hazards regression analysis was applied
to correlate kallikrein staining with patient survival. Pre-
vious analysis of this patient cohort demonstrated that
elevated KLK6-IR was associated with decreased patient
survival (hazard ratio [HR] = 1.16, 95 % confidence inter-
val [CI] = 1.02–1.31, P = 0.02; Table 2) [5]. The current
analysis additionally demonstrated that elevated KLK7-
IR is associated with poor patient prognosis (HR = 1.17,
CI = 1.02–1.34, P = 0.03; Table 2). Moreover, as the per-
cent of the tumor core stained positive for KLK6 or KLK9
increased, survival decreased (HR = 1.63, CI = 1.06–2.50,
P = 0.03 and HR = 2.25, CI = 1.21–4.22, P = 0.01, re-
spectively; Table 2). After multivariable Cox modeling,
utilizing gender, ECOG performance and age as covariates,
the association of kallikreins with survival was no lon-
ger significant. However, when only gender and ECOG
performance scores were included as covariates in the
multivariable analysis, scores for KLK6-IR and KLK9 %
tumor core stained, retained their significant associ-
ation with survival (HR = 1.15, CI = 1.01–1.30, P = 0.03
and HR = 2.13, CI = 1.12–4.05, P = 0.021, respectively;
Table 3).
Martingale residuals from the Cox proportional haz-
ards regression model were used to assess the functional
form of kallikrein parameters and when appropriate
dichotomize the patients into groups. As we recently re-
ported, patients with a KLK6-IR < 10 (n = 48) have a me-
dian survival of 408 d, while patients with KLK6-IR ≥ 10
(n = 12) have a significantly shorter survival time, 276 d
(HR = 2.36, CI = 1.19–4.68, P = 0.014; Table 3 and Fig. 3)
[5]. This comparison remained significant when the data
were adjusted for gender and ECOG performance scores
(HR = 2.4, CI = 1.20–4.78, P = 0.01; Table 3). Patients
with KLK6 % < 3 (n = 32) had a median survival of 419
d; patients with KLK6 % ≥ 3 (n = 28) had a significantly
shorter median survival of 320 d (HR = 2.07, CI = 1.14–
3.76, P = 0.017; Table 3 and Fig. 3). Multivariable analysis
of KLK6 % tumor core stained showed a significant cor-
relation with survival, utilizing gender and ECOG as co-
variates (HR = 1.93, CI = 1.03–3.63, P = 0.04; Table 3).
Patients with KLK7-IR < 9 (n = 38) had a median survival
of 422 d; patients with KLK7-IR ≥ 9 (n = 22) had a sig-
nificantly shorter median survival of 294 d (HR = 2.15,
CI = 1.20–3.87, P = 0.01), which remained significantly
different after adjustment for gender and performance
score (HR = 2.04, CI = 1.10–3.77, P = 0.024). Patients
with KLK9 % tumor core stained < 4 (n = 29) had median
survival of 422 d; patients with KLK9 % tumor core
stained = 4 (n = 31) had a median survival of 311 d (HR
= 1.70, CI = 0.98–2.95, P = 0.061; Table 3 and Fig. 3).
Discussion
Through a comprehensive parallel analysis of immuno-
reactivity for six kallikreins in grade III and IV astrocy-
toma we determined that tumor core staining for KLK7
and KLK9, like KLK6, has significant prognostic value
with regard to patient survival. Specifically, higher tumor
core levels of KLK6, KLK7 and KLK9 were each associ-
ated with reduced GBM patient survival. These findings
highlight the likely significance of each of these secreted
serine proteases to the pathophysiology of high-grade
glioma and the need for additional studies to define the
mechanism of action, significance to therapy resistance
and their potential utility as therapeutic targets to im-
prove patient outcomes.
Prior studies demonstrate that higher levels of KLK6
immunoreactivity in grade IV astrocytoma are associated
with poor patient survival [5]. Expression of KLK6 RNA
Table 2 Astrocytoma survival association with kallikrein protein
expression
Univariable Adjusteda
HR 95 % CI P HR 95 % CI P
KLK1
Intensity 0.93 0.49–1.78 0.83 1.10 0.54–2.23 0.80
Percent 1.21 0.81–1.80 0.36 1.41 0.92–2.15 0.11
IR 1.08 0.96–1.21 0.21 1.13 0.99–1.29 0.06
KLK6
Intensity 0.89 0.42–1.90 0.77 0.73 0.32–1.68 0.46
Percent 1.63 1.06–2.50 0.03* 1.35 0.87–2.10 0.18
IR 1.16 1.02–1.31 0.02* 1.10 0.96–1.25 0.17
KLK7
Intensity 1.25 0.61–2.56 0.54 0.95 0.45–2.03 0.90
Percent 1.96 0.91–4.22 0.09 1.91 0.87–4.19 0.11
IR 1.17 1.02–1.34 0.03* 1.10 0.95–1.28 0.20
KLK8
Intensity 0.87 0.46–1.66 0.68 0.84 0.40–1.78 0.65
Percent 0.91 0.66–1.25 0.54 0.96 0.68–1.36 0.81
IR 0.98 0.83–1.16 0.81 0.95 0.77–1.17 0.61
KLK9
Intensity 0.65 0.38–1.13 0.13 0.64 0.36–1.14 0.13
Percent 2.25 1.21–4.22 0.01* 1.68 0.86–3.30 0.13
IR 1.05 0.90–1.22 0.52 0.99 0.85–1.16 0.90
KLK10
Intensity 1.14 0.59–2.20 0.70 0.99 0.46–2.12 0.97
Percent 0.99 0.66–1.48 0.94 1.10 0.72–1.69 0.67
IR 1.12 0.92–1.37 0.27 1.03 0.82–1.28 0.80
Cox proportional hazards regression analysis assessing the association of
kallikrein protein expression in 60 grade IV astrocytoma specimens. *P ≤ 0.03,
Cox proportional hazards regression analysis
aAdjusted for age, gender and performance score
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is also linked to poor patient survival in a group of intra-
cranial malignancies, including glioblastomas, meningi-
omas, oligodendrogliomas, ependymomas and other rare
malignancies and brain metastases [12]. KLK6 expres-
sion is associated with an unfavorable prognosis in ovar-
ian [3] and colorectal cancers [22]. In contrast, KLK6
expression in breast cancer appears to have a protective
role, with elevated expression being linked to reduced
proliferation and tumorigenicity. Expression of KLK6 is
also reduced in metastatic lymph nodes [23].
Paralleling what we have reported for KLK6 [5], results
herein suggest that elevated levels of KLK7 expression
are associated with poor patient survival. Supporting
this, a prior study examining a mixed cohort of intracra-
nial malignancies similarly demonstrated that elevations
in KLK7 expression are associated with poor patient sur-
vival [13]. Both studies support the idea that KLK7 ex-
pression leads to more aggressive brain tumors. KLK7 is
also associated with reduced survival times in ovarian
[24], breast [25] and colon cancer [26]. By contrast, the
current study and prior efforts suggest that changes in
KLK8 expression in GBM or other intracranial malig-
nancies have little association with prognosis [13]. In
head and neck squamous cell carcinoma, KLK8 expres-
sion is down regulated in metastases, but it is not associ-
ated with improved survival [27]. Pointing to potential
cancer-type specific effects as described for KLK6, KLK8
is a favorable prognostic indicator in ovarian cancer
[28], but an unfavorable indicator in lung cancer [29].
The current study provides the first evidence that
KLK9 protein expression may be associated with poor
prognosis in glioma patients. Again pointing to potential
tumor specific effects of kallikreins, KLK9 was previ-
ously found to be expressed at higher levels in low grade
breast and ovarian cancers [30, 31]. In breast cancer,
KLK9 expression was also higher in patients with
smaller tumors and was associated with increased pa-
tient survival, particularly patients that are estrogen and
progesterone receptor negative [31]. In the case of ovar-
ian cancer, KLK9 expression is a predictor of longer
overall survival in patients with lower grade tumors [30].
Specific regulatory patterns of kallikreins across cancers
may be related to hormone regulation, as proposed for
KLK9 in both breast and ovarian cancer. Interestingly,
KLK10 is a proposed tumor suppressor gene in breast
carcinoma cell lines, blocking tumorigenicity in an
Table 3 Survival analysis of immunohistochemical scores after cut point analysis
Univariable Analysis Multivariable Analysis
N Median Survival Hazard Ratio 95 % CI Pa Hazard Ratio 95 % CI Pa
KLK6 % 60 355 1.63 1.06–2.50 0.027 1.35 0.87–2.10 0.18b
1.55 1.10–2.40 0.052c
<3 32 419
≥3 28 320 2.07 1.14–3.76 0.017 1.36 0.72–2.57 0.34b
1.93 1.03–3.63 0.04c
KLK6-IR 60 355 1.16 1.02–1.31 0.020 1.10 0.96–1.25 0.17b
1.15 1.01–1.30 0.03c
<10 48 408
≥10 12 276 2.36 1.19–4.68 0.014 1.72 0.84–3.54 0.14b
2.4 1.20–4.78 0.01c
KLK7-IR 60 355 1.17 1.02–1.34 0.025 1.10 0.95–1.28 0.20b
1.15 1.00–1.32 0.057c
<9 38 422
≥9 22 294 2.15 1.20–3.87 0.010 1.47 0.77–2.80 0.24b
2.04 1.10–3.77 0.024c
KLK9 % 60 355 2.25 1.21–4.22 0.011 1.68 0.86–3.3 0.13b
2.13 1.12–4.05 0.021c
<4 29 422
=4 31 311 1.70 0.98–2.95 0.061 1.42 0.79–2.57 0.24b
1.58 0.89–2.79 0.12c
Cox proportional hazards regression analysis assessing the association of kallikrein protein expression with patient survival in 60 grade IV astrocytoma specimens
aProportional hazards regression
bAdjusted for age, gender and performance score
cAdjusted for gender and performance score
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in vivo breast cancer model [32]. However, underscoring
the importance of considering tumor-type specific ef-
fects, KLK10 has been found to be an unfavorable prog-
nostic indicator in gastric, colorectal and ovarian cancer
[33–35]. Here we report that KLK10 expression is in-
creased with astrocytoma grade, but no association with
patient survival was observed.
Our previous studies demonstrate that KLK6 over ex-
pression promotes resistance of GBM cell lines to cell
death inducing agents, including radiation and temozo-
lomide, the current standard of GBM patient care [5].
Interestingly, the KLK6-mediated activation of PAR1
was shown to play an essential role in its ability to pro-
mote glioma cell survival [5]. Notably, KLK6 also pro-
motes survival of the Jurkat leukemia T cell line in a
PAR1 dependent fashion [36]. In melanoma cells, PAR1
is activated by KLK6 promoting intracellular calcium
flux and tumor cell invasion [37]. Together these studies
support the concept that KLK6 mediates its effects in
astrocytoma cells in a PAR1-dependent fashion and that
this is likely to involve both cell survival and invasion.
KLK7 overexpression increases cell invasion in glioma
cell lines in vitro matrigel assay [13]. Moreover, overex-
pression of KLK7 in colon cancer cell lines promotes
proliferation and tumorigenicity [38]. The signaling
pathways participating in KLK7-mediated effects in
tumor cells have not been elucidated, but effects on cell
invasion and proliferation may account for the shortened
survival times we observe in GBM patients with elevated
tumor KLK7 expression.
The current studies are among the first to examine
KLK9 in malignancy and results of interest since eleva-
tions in tumor KLK9 were found to be associated with
higher grade gliomas. These findings point to the need for
additional studies to determine the biological effects of
kallikreins in glioma malignancy and whether these effects
are mediated by PAR-dependent and/or independent ac-
tions, such as extracellular matrix turnover. In addition to
Fig. 3 Kaplan-Meier curves for overall survival of grade IV astrocytoma patients Curves are shown for (a) KLK6 % of tumor core stained of≤ 3
or > 3, (b) KLK6-IR scores of < 10 or ≥ 10, (c) KLK7-IR scores of < 9 or ≥ 9, and (d) KLK9 % of tumor core stained of < 4 or = 4. P values shown are
based on proportional hazards regression
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direct effects on tumor cell behavior, it is also possible that
the kallikreins identified herein participate in activation,
or inactivation, cascades with other kallikreins or enzymes
involved in the fibrinolytic or thrombolytic systems [21].
Conclusion
Data presented here demonstrate that elevated levels of
KLK6, KLK7 and KLK9 proteins are associated with
poor GBM patient survival. Our prior studies suggest
that KLK6 directly promotes glioma cell survival, includ-
ing resistance to radiation and temozolomide, in a
PAR1-dependent manner. The current work therefore
points to the need for additional studies to determine
the potential pathophysiological roles of KLK7 and
KLK9 in glioma malignancy and any parallel involve-
ment of PAR-activation in mediating their effects. This
knowledge will be key to potential future studies in
which kallikreins or the receptors they activate could be
targeted therapeutically to improve patient survival. Im-
portantly, the current results suggest future studies to
determine any impact of elevated kallikrein levels on
therapy responsiveness. Finally, analysis of the mecha-
nisms by which kallikreins are elevated in GBM, albeit
by gene duplications, hormonal regulation, epigenetic
changes, or other means, will be of interest and poten-
tially important to understanding the differential expres-
sion and outcomes these novel serine proteases exert
across a wide range of malignancies.
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